GO
| HSI1 | 23,919.50 | 0.00 | -- |
| HSCEI1 | 8,057.59 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
SBP GROUP (01177.HK) Reaches Collaboration With Boehringer Ingelheim, Potential Proceeds USD7 Billion
2026-11-04 16:47:40 SBP GROUP (01177.HK) announced that the group has entered into a strategic option and licensing agreement with Boehringer Ingelheim. This marks the second collaboration between the two parties in the oncology field, with both sides committed to establishing a long-term strategic partnership. The agreement covers six preclinical asset projects involving antibody-drug conjugates (ADC) and T-cell engagers (TCE). Five of the projects are from the group's wholly-owned subsidiary LaNova Medicines, while one project is from the group's subsidiary Beijing Tide. Under the agreement, the group will lead the early-stage development of these projects until completion of global Phase I clinical trials. Upon achieving agreed clinical milestones, Boehringer Ingelheim will have the option to obtain exclusive rights for the development, manufacturing and commercialization of four projects globally (excluding China, Hong Kong and Macau), and the remaining two projects on a worldwide basis. The group will receive upfront and near-term payments of USD358 million, and will also be eligible to receive potential option exercise, development, regulatory and commercialization milestone payments totaling up to USD7 billion, as well as tiered royalties of up to the low double-digit percentage based on future product sales. (sl/ad)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |